L. Pike

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

M. Dennis, S. Oliver, M. Davies, 2012, Cancer Chemotherapy and Pharmacology.

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

M. Gore, P. Mulders, E. Porfiri, 2012, European journal of cancer.

Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).

Ying Cheng, Tae Won Kim, T. Pintér, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of baseline CEA, VEGF, and soluble VEGF receptor-2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC).

P. Hoff, L. Pike, S. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

49LBA Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)

M. Gore, P. Mulders, E. Porfiri, 2009 .

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid leukemia

H. Kantarjian, G. Martinelli, A. Quintás-Cardama, 2013, Cancer.

Routine educational outcome measures in health studies: Key Stage 1 in the ORACLE Children Study follow-up of randomised trial cohorts

S. Kenyon, N. Marlow, A. Salt, 2010, Archives of Disease in Childhood.

Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer.

S. Kopetz, D. Cunningham, H. Tran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.